More recently, the linkage of GOF alterations in NFE2L2 with cancer progression and an inefficient response to classical cancer treatments (radiotherapy and chemotherapy) in tumors with active NRF2 [21,22,23] support that NRF2 might act as a tumor driver in several cancer sub-types (particularly in LUAD and LUSC). Here, NFE2L2 is linked to neoplasm.